WARNING:
JavaScript is turned OFF. None of the links on this concept map will
work until it is reactivated.
If you need help turning JavaScript On, click here.
This Concept Map, created with IHMC CmapTools, has information related to: PE cmap, Depends on LDL levels Optimal mg/dL High Lower LDL ᡠ%, Responsible for relaxation & contraction of the BV and releases substances which control blood clotting and immunity of the body Pathophysiology between PAD & PVD Arterial & Venous Insufficiency, Inhibits HMG-CoA reductase conversion to mevalonate, a precusor of sterols, cholesterol. ???? ↓ Isoprenylated protein, Lower LDL ណ% ???? Atorvastatin 5 mg, ↓ Isoprenylated protein ???? other systems, Causes 'oxidative stress' & imbalance in the functioning of endothelial cells leading to ↑ Local mediators, PAD Peripheral Artery Disease physical symptoms discoloration of toes, ↓ Hepatic Cholesterol ???? ↑ SREBP2, Warfarin 5 mg MOA Vitamin K epoxide reductase inhibitor, ↓ Isoprenylated protein ???? Cardiovascular system, Deep Vein Thrombosis (DVT) Blood clot in the legs Swelling Pain Warmth Blue-Purple discoloration, Fish Oil omega-3 lowers bodys production of triglycerides, Circulatory Statis ???? Immobility Venous Obstruction (obesity) Varicose veins Afib or LV dysfunction, ↑ Tissue ACE-A II Growth factors matrix Vascular lesion & remodeling, Pleiotropic effects ???? Cardiovascular system, PAD Peripheral Artery Disease physical symptoms thin, shiny skin, Endothelial Dysfunction Case Patient JE 54 YOM 250 lb Retired Truck Driver, Lower LDL 30%-40% ???? Atorvastatin 10-20 mg d, Lipid- Lowering effects ???? ↓ TG-VLDL, Current medication Anticoagulant (arterial & venous thrombosis) Warfarin 5 mg